Melanoma is one of the most highly mutated malignancies, largely as a function of its generation through ultraviolet light and other mutational processes. The wide array of mutations in both "driver" and "passenger" genes can present a confusing array of data for practitioners, particularly within the context of the recent revolutions in targeted and immune therapy. Although mutations in BRAF V600 clearly confer sensitivity to BRAF and mitogen-activated protein kinase kinase (MEK) inhibitors, the clinical implications of most other mutations are less often discussed and understood. In this review, we provide an overview of the high-frequency genomic alterations and their prognostic and therapeutic relevance in melanoma.
INTRODUCTION
Cancer therapeutics have been dramatically reshaped over the past 15 years by nearly concurrent revolutions in precision medicine-driven targeted therapies and novel cancer immune therapies. The detection of particular actionable mutations driving the growth and progression of several cancers has led to the development of small-molecule kinase inhibitors and/ or monoclonal antibodies, which in turn have improved clinical outcomes. [1] [2] [3] [4] [5] Coupled with the development of proteindirected antibody therapies (eg, rituximab, trastuzumab, bretuximab vedotin, cetuximab, etc), hormone-directed therapies (eg, tamoxifen and enzalutamide), angiogenesis-targeted therapies (eg, vascular endothelial growth factor inhibitors), and cell-cycle kinase inhibitors, these precision medicine-type approaches have dramatically improved therapeutic outcomes in many solid and hematologic cancers. Immunotherapies, agents that target programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have similarly revolutionized a partially overlapping group of cancers. These agents frequently present superior toxicity profiles, and produce rapid and/or durable responses.
Central to the development of these therapies, particularly mutation-directed approaches, has been the ability to molecularly profile tumors in the clinic. Although this type of technology was completely unavailable before the human genome project in 2001, 6, 7 rapid advances have permitted the now routine sequencing of large fractions of the cancer genome. As such, determining the presence of relevant therapeutic mutations now is a routine procedure in many cancers, particularly melanoma, non-small cell lung cancer (NSCLC), colon adenocarcinoma, and others. Although a few mutations have clear therapeutic implications, the majority of detected mutations have less well-defined clinical relevance. Thus, next-generation sequencing platforms that sequence hundreds of genes (eg, Foundation Medicine, Cambridge, Mass, Caris Life Sciences, Dallas, Texas) can provide a figurative mountain of genomic data through which to parse. In particular, a highly mutated tumor such as melanoma may yield data that are challenging for the practitioner to interpret. Herein, we discuss the clinical and biologic implications of common mutations and other genomic alterations in melanoma.
Melanoma Is Highly Mutated
One consideration is that the mutation rate is widely variable between human cancers. The somatic mutation frequency rate in 3083 matched tumor-normal pairs from 27 different tumor types, including pediatric tumors, hematologic malignancies, and solid tumors, was analyzed for the median frequency of nonsynonymous mutations. The analysis revealed a 1000-fold variation across the different tumor types. In melanoma, the frequency of somatic mutations ranged widely from 0.1 to 100 per Megabase (MB) position, but overall had the highest mutation frequency of all cancers analyzed. 8 The variability in the mutation frequency in melanoma may be attributed to the presence or absence of a known carcinogen, such as ultraviolet (UV) exposure.
The landscape of genomic alterations in cutaneous melanoma is wide-ranging. Data published with The Cancer Genome Atlas (TCGA) found that when wholeexome sequence analysis of 333 patients with primary and/or metastatic melanoma was performed, melanomas could be classified into 4 genomic subtypes: mutant BRAF, mutant NRAS, mutant neurofibromatosis type 1 (NF1), and triple-wild-type. 9 The different genomic subtypes may be of predictive value given the therapeutic targets currently available. The TCGA database and other key sequencing studies have provided a comprehensive survey of the genetic landscape of melanomas. 10 In patients with melanoma, the activated BRAFmutated kinase can be inhibited by BRAF-targeting drugs, and its downstream protein mitogen-activated protein kinase kinase (MEK) can be inhibited by a MEKtargeted drug. The combination of targeted inhibitors has had a very significant impact on survival in patients with BRAF-mutant melanoma, with a median overall survival (OS) exceeding 2 years. 11 Conversely, the other common genomic subtypes, including mutant NRAS, mutant NF1, and triple-wild-type, to our knowledge have not been effectively targeted to date.
Mutation Patterns: UV is the Key
Mutation patterns vary substantially between melanoma subtypes, both in terms of total numbers of mutations (single-nucleotide variants) and driver oncogenes (Table 1) . 10 Melanomas from chronically sun-exposed skin tend to have the highest numbers of mutations, and often have NF1, NRAS, and occasionally BRAF V600K mutations present.
12 BRAF V600E mutations, by contrast, are rare in these melanomas. Melanomas from intermittently sun-exposed skin frequently have intermediate numbers of mutations, and have mutations in BRAF V600E (50%) or NRAS (15%-20%). Tumors arising from noncutaneous sites (mucosal, acral, or uveal) have significantly lower total numbers of mutations by several orders of magnitude, with uveal melanoma being a particularly genomically simple tumor, thus demonstrating that UV light is not the only driver of melanogenesis. Age also is a factor, with younger patients (those aged < 40 years) more likely to have BRAF V600E mutations. Acral melanomas arising on the palms, soles, and nailbeds have mutations in BRAF, NRAS, and KIT in approximately 15% of cases each. Mucosal melanomas, by contrast, have only infrequent BRAF or NRAS mutations, but have KIT mutations in approximately 15% of cases (primarily in genitourinary or anal, rather than sinonasal, melanomas). Uveal melanomas have completely distinct genomic patterns, and harbor mutations either in G protein subunit alpha Q (GNAQ) or G protein subunit alpha 11 (GNA11) in > 90% of cases, whereas BRCA1-associated protein 1 (BAP1), splicing factor 3b subunit 1 (SF3B1), and EIFAX generally are distinct subsets and nonoverlapping.
Notwithstanding the less common noncutaneous melanomas, UV light is the major driver of mutagenesis in cutaneous melanomas. Although it remains challenging to conclusively model the role of UV light in melanoma, a wealth of observational studies have unequivocally associated this carcinogen with melanoma generation. 13 UV light produces a distinct mutational signature, with C>T and CC>TT transitions. It is interesting to note that melanoma precursors have been reported to progress through a stereotypical pattern of mutagenesis in many cases. 14 Unequivocally benign lesions (nevi) harbored only BRAF V600E mutations. Intermediate lesions acquired other mutations, such as telomerase reverse transcriptase (TERT) promoter mutations or, by contrast, had NRAS mutations. Invasive melanomas often acquired cyclindependent kinase inhibitor 2A (CDKN2A) loss, phosphatase and tensin homolog (PTEN) loss, or TP53 mutations. Furthermore, point mutations increased at each stage of evolution. This study reinforced findings from in vitro models, specifically that BRAF V600E mutations alone are insufficient to drive oncogenesis and require additional genetic "hits," and that UV light was the major driver of mutagenesis. Although UV light is a major culprit in driving mutagenesis and disease progression, other pathways, such pheomelanin-generated oxidative damage in the red hair/fair skin phenotype, were exemplified by patients or mice with MC1R gene polymorphisms. 15 Other germline polymorphisms, such as those in CDKN2A, are linked with higher incidences of melanoma. 16 Many Mutations: Does It Matter?
Until recently, the total number of mutations present in a tumor was not considered to be of major clinical relevance. At the low end of the spectrum, with <1 mutation per MB of DNA, are most hematologic malignancies and childhood cancers. 8 Many common adult solid tumors, such as breast, colon, prostate, and pancreatic cancers, harbor mutation burdens slightly higher than this, but still almost always <5 mutations per MB. On the higher end
Mutations in Melanoma/Davis et al of the spectrum, carcinogen-induced cancers, including cancers of the cervix, bladder, head and neck, and lung, typically have a median of 5 to 10 mutations per MB, although intratumoral variation is quite high. Melanoma is at the highest end of the spectrum, with a median of >10 mutations per MB and many tumors with 10-fold greater mutation numbers. It is interesting to note that normal human skin also has been found to have approximately 2 to 6 mutations per MB, similar to many solid tumors. 17, 18 On average, the only other cancer subsets more highly mutated than melanoma are those with microsatellite instability or POLE mutations, in which DNA repair is impaired.
One feature of melanoma that on the surface appears to be unrelated to passenger mutations is its high degree of response to immune therapy. Melanoma historically has been thought of as an immune-responsive cancer. Indeed, the only effective historical therapies for metastatic disease were interleukin 2 and adoptive cell therapy. 19, 20 More recently, immune checkpoint inhibitors have further transformed the treatment of metastatic melanoma. In particular, single-agent nivolumab (anti-PD-1) produces a response rate of approximately 45%, and combination ipilimumab (anti-CTLA-4) and nivolumab result in a response in nearly 60% of patients. 21 Reliable biomarkers to predict response, and indeed the causative factors underlying responses in individual patients, have been somewhat elusive.
Several studies have demonstrated intriguing predictive and perhaps causative links between mutational burden and response to immunotherapy. The initial assumption in these and other studies referenced below is that putative "passenger" mutations actually function to generate so-called neoantigens, peptides that may be recognized as foreign to the adaptive immune system. 22 These neoantigens generate a preexisting immune response that may be unleashed by checkpoint blockade. This model may be simplistic because other studies have suggested that mutational burden is not linked with preexisting immune signatures. 23 Regardless of the mechanism, mutation burden has been clearly linked in multiple tumor types with response to immune therapy.
To our knowledge, the first study involved a cohort of patients treated with ipilimumab. In this study, patients who had durable clinical benefit (>6 months of stable or responsive disease) had substantially higher mutation numbers compared with those who failed to respond. 24 Initially, a tetrapeptide signature corresponding to viral or bacterial sequences was reported, suggesting that mutations may generate microbial-like sequences susceptible to immune targeting. A subsequent large sequencing study failed to replicate the tetrapeptide signature associations, although it redemonstrated strong associations between ipilimumab benefit and high mutation burdens. 25 Anti-PD-1 benefit in patients with melanoma also has been linked with high mutation burdens. Two studies that performed whole-exome sequencing on pretreatment melanoma samples found that high mutation numbers correlated with improved clinical outcomes after treatment. 26, 27 Other studies also have strongly correlated mutation load, as determined by whole-exome sequencing, with improved clinical outcomes to anti-PD-1 in patients with NSCLC 28, 29 and microsatellite-unstable cancers. 30, 31 Although whole-exome sequencing provides comprehensive genomic characterization of tumors, it remains impractical to perform in routine clinical practice, given the requirement for matched germline tissue and extensive informatics support. Our group and others evaluated whether mutation burden in smaller, clinically useful gene panels (comprised of 170-315 genes) could serve as a useful surrogate for total exonic mutation burden. These studies demonstrated that predicted mutation burden correlated strongly with total exonic mutation load and, more important, with immunotherapy responses. Among 65 patients with melanoma, mutation burden calculated using FoundationOne (315 genes) was found to be strongly associated with response, progression-free survival (PFS), and OS, particularly at high (>20 mutations/ MB) levels. NF1 mutations, likely as a surrogate for highly mutated melanomas, also correlated with improved clinical outcomes. These findings using FoundationOne were redemonstrated in a prospectively accrued cohort of patients with urothelial bladder carcinoma who were treated with atezolizumab. 32 Mutation burden calculated with a platform of 170 genes performed at The University of Texas MD Anderson Cancer Center in Houston also correlated with response to ipilimumab and adoptive Tcell therapy (in patients with melanoma) and anti-PD-1 (in patients with NSCLC). 33 Thus, mutation load using smaller panels may serve as a biomarker of response to immunotherapy. Our group is conducting a clinical trial of nivolumab in patients with highly mutated NSCLC who have not received any prior treatment. The impact of mutation load on combination immunotherapy strategies (eg, ipilimumab/nivolumab) is not known.
Finally, although overall mutation load has been correlated with immunotherapy response, there is intensive research to identify immunogenic neoantigens. If identified, vaccines or perhaps cellular therapies could be designed against neoantigens of interest. Two elegant, proof-of-concept studies recently were published, demonstrating the preliminary clinical activity of this concept. 34, 35 Specific mutations
BRAF
In 2002, BRAF mutations were found to occur frequently in up to 66% of patients with melanoma. 36 These activating mutations in BRAF result in constitutive activation of kinase function, independent of upstream signaling from RAS. BRAF interacts with MEK, resulting in MEK phosphorylation, leading to subsequent activating phosphorylation of extracellular signal-regulated kinase (ERK), ultimately promoting cellular growth and inhibiting apoptosis. 37 Subsequent studies have confirmed the incidence of BRAF mutations as approximately 40% to 50% in patients with cutaneous melanoma (Fig. 1) . 9, 38, 39 The most common mutation in BRAF is a substitution of glutamic acid for valine at amino acid 600 (V600E), accounting for 70% to 88% of all BRAF mutations. 9, 38, 40 Less common mutations in BRAF include V600K, V600R, and V600M, comprising 11% to 20%, 2% to 5%, and 1% to 4%, respectively, of BRAF mutations. 9, 38, 39 Other, non-V600 alterations in BRAF occur in approximately 5% of all melanomas, most commonly at codons 466, 469, 597, and 601, and BRAF fusions.
Melanomas that arise on skin with intermittent sun exposure are more likely to have a BRAF mutation compared with melanomas occurring on chronically sunexposed skin, unexposed skin, or mucosal melanomas. 41 Other clinicopathologic features that have been associated with BRAF-mutant melanoma include younger age, superficial spreading or nodular melanoma, presence of mitoses, occult primary melanoma, and truncal location. 38 To the best of our knowledge, the relationship between melanocytic nevi and the development of melanoma is incompletely understood. BRAF mutations are an acquired event and are found in 70% to 80% of nevi, and tend to occur more often in melanomas arising from preexisting nevi. However, the majority of nevi will not progress to melanoma. BRAF mutations are frequent in melanocytic nevi and vertical growth phase melanomas but are infrequent in radial growth phase and in situ melanomas. [42] [43] [44] Thus, although BRAF mutations clearly drive melanoma growth and progression, they are insufficient by themselves to induce melanomas. Melanomagenesis requires cooperation between mutant BRAF and other pathways. Mouse models have demonstrated that concurrent BRAF-activating mutations and PTEN-inactivating mutations result in melanomagenesis. [45] [46] [47] In addition, mice with BRAF V600E mutations as well as CDKN2A loss develop larger melanocytic nevi, with a very small percentage progressing to melanoma. However, when BRAF/ CDKN2A-mutant mice also have loss of Lkb1, they demonstrate marked activation of mTORC2/Akt, resulting in rapidly progressive melanomas. 45, 48 These findings demonstrate some of the complexities underlying melanomagenesis and the need for further understanding of the relationship between BRAF and other mutations.
The key clinical relevance of BRAF mutations lies in their response to BRAF and/or MEK inhibitors. Available evidence has suggested that various BRAF V600 mutations have a similar capacity to respond to these therapies, although response rates may be less with V600K mutations compared with V600E. 49 Several initial phase 3 trials have demonstrated the superiority of single-agent BRAF and MEK inhibitors compared with chemotherapy. [50] [51] [52] Subsequently, combining these agents has demonstrated superiority to single-agent therapy, with PFS Cancer September 1, 2018 Mutations in Melanoma/Davis et al reported to be in the range of 12 months, and response rates of nearly 70%. 11, 53 Thus, combined BRAF/MEK inhibition is a pillar of standard therapy for patients with metastatic melanoma. More recently, combined dabrafenib and trametinib have demonstrated improved PFS and OS in patients with high-risk, resected melanoma compared with observation alone. 54 It is important to note that available evidence suggests that BRAF mutations predispose toward a response to BRAF/MEK inhibition in other cancers, including lung cancer, thyroid cancer, and hematologic malignancies. By contrast, colon cancers appear relatively insensitive to pathway inhibition. This finding highlights important differences in the tissue type and concurrent genetic composition, and underscores the importance of dissecting clinical activity data in different cancer types.
A number of extensive studies have assessed the genomic correlates of both acquired and intrinsic resistance to BRAF inhibitors. A variety of mutations appear to arise within the context of acquired resistance, and reignite mitogen-activated protein kinase (MAPK) signaling (or parallel signaling networks) despite the presence of BRAF inhibition, and include mutations in NRAS, phosphoinositide 3-kinase (PI3K)/AKT pathway members, and amplification and alternative splicing of BRAF. [55] [56] [57] Unraveling intrinsic resistance has been a greater challenge, although preexisting mutations in PTEN and mitogen-activated protein kinase kinase 1 (MAP2K1) appear to correlate with shorter responses. 58, 59 These mutations, however, do not preclude therapeutic responses.
The 5% of melanomas harboring non-V600 mutations have less clear therapeutic relevance. Responses to MEK inhibitors and pan-RAF inhibitors (eg, sorafenib) have been reported in patients and using in vitro models. [60] [61] [62] We currently are conducting a clinical trial of trametinib in patients with non-V600 BRAF mutations. In addition, one arm of the National Cancer Institute-MATCH (Molecular Analysis for Therapy Choice) study is testing trametinib in this same population across cancer types. It remains controversial whether to select targeted therapy (BRAF/MEK inhibitors) or immune therapy as the initial therapy in the BRAF-mutant population. Ideally, we would be able to determine molecular or clinical biomarkers to help guide these decisions. At this time, it appears the majority of clinical factors that correlate with response to BRAF/MEK inhibitors also occur in patients who have good outcomes with immunotherapy (eg, those with low disease burden, low lactate dehydrogenase levels, and good functional status). 63 One randomized study currently is comparing dabrafenib and trametinib with ipilimumab and nivolumab as first-line therapy with planned crossover at the time of disease progression. Until these data are available, we intend to treat patients with bulky or symptomatic disease with BRAF/MEK inhibitors to induce a rapid response, and to treat the majority of other patients with front-line immunotherapy.
NRAS
The RAS family includes 3 primary proto-oncogenes, NRAS, KRAS, and HRAS, that regulate cell proliferation and apoptosis. NRAS mutations constitutively activate the MAPK, PI3K, and other cell signaling pathways, causing cell growth, proliferation, and cell cycle dysfunction. NRAS mutations occur in >20% of patients with cutaneous melanoma, most commonly in codon 61 and less often in codons 12 and 13. 9, 64 Melanomas with NRAS mutations are associated with an aggressive clinical course and a poor prognosis. They are more common in nonsun-exposed skin. 65 To the best of our knowledge, the treatment of NRAS-mutant melanoma has been met with limited success to date. Initial early responses to the MEK inhibitor binimetinib led to a phase 3 study in which binimetinib was compared with chemotherapy in patients with NRASmutant melanoma. Surprisingly, although response rates (15% vs 9%; P 5 .02) and PFS (median of 2.8 months vs 1.5 months; P < .001) were found to be modestly improved with binimetinib, no difference in OS was observed (11 months vs 10.1 months; P 5 .5). 66 Thus, the further development of binimetinib monotherapy in patients with NRAS-mutant melanoma is unlikely to be pursued. One study suggested that NRAS mutations may correspond with response to anti-PD-1, but the sample size was small. 67 It is interesting to note that outcomes to binimetinib in patients with prior receipt of immunotherapy appeared to be superior, suggesting that the combination of MEK inhibitors and immunotherapy could be useful in this population. Ongoing studies currently are evaluating the efficacy of MEK inhibitors combined with cyclin-dependent kinase (CDK) 4/6 inhibitors.
KIT
KIT is a proto-oncogene receptor tyrosine kinase that is found on the cell membrane and binds to stem cell factor. This activates the KIT protein, resulting in the activation of multiple signaling pathways affecting cell growth, proliferation, survival, and migration. Mutations in KIT occur in 1% to 3% of all melanomas and are most commonly found in exon 11 (L576P) or exon 13 (K642E).
68
KIT mutations are more commonly found in acral or mucosal melanomas (approximately 15% each, and in vulvovaginal more often than sinonasal melanomas) and in areas of chronic sun damage (approximately 2%). 69, 70 Tyrosine kinase inhibitors, particularly imatinib, have demonstrated some activity in the treatment of KITmutant melanoma. Responses to treatment in patients with exon 11 mutations occur in the range of 30% to 50%, although acquired resistance typically occurs within 1 year. 71, 72 Conversely, KIT amplification does not appear to mediate imatinib sensitivity.
NF1
The NF1 gene product is a GTPase-activating protein that dampens MAPK signaling by downregulating RAS activity, and mutations and/or loss of NF1 lead to MAPK activation. NF1 mutations define the third most common genomically defined subset of melanomas, and were reported to occur in approximately 14% of TCGA melanoma samples, including up to 70% of BRAF/NRAS wild-type samples. 9 The majority of NF1 mutations lead to a loss of function of this tumor suppressor, with approximately 80% of patients having a nonsense mutation, an insertion, or a deletion that leads to a truncated protein. 73 In co-occurring BRAF/NF1-mutant tumors in mice, there is insensitivity to BRAF inhibitor therapy, presumably due to NF1 loss of function leading to the dysregulation of the PI3K/AKT/mammalian target of rapamycin (mTOR) pathway. 74 There are preclinical data to suggest that NF1 loss may lead to MEK inhibitor sensitivity; however, to the best of our knowledge, this finding has not clinically translated in a meaningful way. [75] [76] [77] "Pan-RAF" or type 2 RAF inhibitors in combination with MEK inhibitors or PI3K/mTOR inhibitors could be considered
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Other Genomic Subtypes

CDKN2A
TCGA data demonstrated alterations in the RAS/MAPK/ AKT, CDKN2A, and mouse double minute 2 homolog (MDM2)/TP53 pathways in 91%, 69%, and 19% of cases, respectively. 9 Mutations in CDKN2A specifically occurred in 13% of tumors, with approximately another 30% harboring CKDN2A deletions. Mutations in the p16/CDK4/ cyclin D1 pathway have been implicated in melanomagenesis. CDKN2A mutations that result in p16 loss often are observed in familial melanomas. 79 Melanoma genomewide association studies have shown that this pathway may be important in more than just familial melanomas, because genome-wide risk loci have been identified in the CDKN2A and cyclin D1 (CCND1) loci. 80, 81 CDK4 and CCND1 amplifications are noted more frequently in patients with triple-wild-type melanomas. Although it has been hypothesized that mutations in this pathway may contribute to sensitivity to CDK4/6 inhibitors, to our knowledge this has yet to be shown conclusively in the clinic.
82
TP53
TP53 was found to be mutated in approximately 15% of TCGA melanomas, and this appears to occur later during tumor development. 9 The TP53 mutations frequently were found in melanomas harboring any of the major subsets of BRAF-, NRAS-, and NF1-mutated tumors. In comparison, in triple-wild-type tumors, there was an increased prevalence of MDM2 amplifications noted. 9 Currently, agents that inhibit MDM2 (and thus restore wild-type p53 activity) are being combined with BRAF and/or MEK inhibitors.
PTEN
As mentioned, a host of other low-frequency mutations occur in melanoma and are difficult to interpret clinically. PTEN mutations or deep deletions occur in <10% of melanomas and activate P13K/AKT signaling. As mentioned, these may limit response to BRAF inhibition, but also have been implicated in the exclusion of T cells from the tumor microenvironment and a lack of response to immunotherapy. 83 
RAC1
Mutations in Rac family small GTPase 1 (RAC1) occur in approximately 10% of patients with sun-exposed melanomas and tend to co-occur with BRAF or NRAS mutations. In vitro studies have suggested that the primary "hotspot" mutation (RAC1 P29S) activates downstream signaling pathways, thus promoting proliferation and migration. 12 Subsequent studies have suggested that this mutation may regulate PD-L1 expression and mediate resistance to BRAF and MEK inhibitors, although this mutation does not preclude clinical responses. 84, 85 TERT Mutations in TERT are somewhat unique in that they usually occur in the promoter, rather than the coding, region, leading to increased gene expression. These mutations occur in the majority of melanomas, including 69% of all melanomas and 86% of cutaneous melanomas. 86 They are related to UV light exposure (C>T or CC>TT), and have been reported to confer a poor prognosis in one study (median OS, 80 months vs 291 months), although they were not found to be associated with telomere length. 10 
GNAQ/GNA11
Mutations in these G proteins occur in nearly 90% of uveal melanomas and occasionally nonuveal melanomas (but extremely rarely outside of the melanocytic tumor family). 87, 88 These activating mutations trigger MAPK and PI3K/AKT signaling, most likely through RASGRP3 and protein kinase C. 89 The importance of MAPK signaling has led to trials of MEK inhibitors in patients with uveal melanoma, although to the best of our knowledge the results have largely been disappointing. 90 It is interesting to note that several other genomic events correlate with prognosis in uveal melanoma, including SF3B1 mutations (good), BAP1 loss (poor), monosomy 3 (poor), and disomy 3 (good). 87 Other Mutations MYC amplifications occur in up to 8% of melanomas and correlate with poor prognosis and a lack of pigmentation. 91 Other in vitro studies have suggested that MYC amplifications lead to immune exclusion and T-cell dysfunction in the tumor microenvironment. 92 Mutations in the WNT/catenin beta 1 (CTNNB1) pathway (primarily APC and CTNNB1) occur in approximately 10% of melanomas. Although these mutations have less clear clinical implications, CTNNB1 signaling also has been implicated in immune cell exclusion. 93 Finally, low-frequency mutations in ARID2, PPP6C, MAP2K1, IDH1, RB1, and many others have been described. 9, 94 However, to the best of our knowledge, the clinical implications of these mutations remain unclear.
Conclusions
Deciphering the clinical and biologic implications of molecular features, including mutations and other genomic alterations, remains in its early stages. Despite the lack of clear clinical relevance for most mutations, a few salient exceptions exist. BRAF V600 mutations clearly predict sensitivity to inhibitors of BRAF and MEK, as do KIT exon 11 mutations to KIT inhibitors. Furthermore, a high mutation burden correlates with response to singleagent anti-PD-1 therapy. In addition, other mutations such as NRAS or atypical BRAF mutations and others may enable enrollment in clinical trials. These remain the primary clinically actionable findings at this time.
Melanoma has been at the center of revolutions in both precision medicine/targeted therapy and immune therapy. A key challenge for the future includes developing more effective targeted therapies for patients with BRAF wild-type disease; promising combinations include those targeting MEK and CDK4/6. Furthermore, overcoming resistance to BRAF/MEK inhibitors has been a formidable obstacle that could be targeted by ERK inhibitors or next-generation RAF inhibitors. Unraveling the mutational complexities of melanoma continues to be a compelling challenge as we work to improve care for patients with this disease.
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